U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Bennett WL, Wilson LM, Bolen S, et al. Oral Diabetes Medications for Adults With Type 2 Diabetes: An Update [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 Mar. (Comparative Effectiveness Reviews, No. 27.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Oral Diabetes Medications for Adults With Type 2 Diabetes: An Update

Oral Diabetes Medications for Adults With Type 2 Diabetes: An Update [Internet].

Show details

References

1.
Defronzo RA. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773–795. [PMC free article: PMC2661582] [PubMed: 19336687]
2.
Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999–2002. Diabetes Care. 2006;29(6):1263–1268. [PubMed: 16732006]
3.
Cowie CC, Rust KF, Ford ES, et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988–1994 and 2005–2006. Diabetes Care. 2009;32(2):287–294. [PMC free article: PMC2628695] [PubMed: 19017771]
4.
Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care. 2003;26(3):917–932. [PubMed: 12610059]
5.
Skyler JS, Oddo C. Diabetes trends in the USA. Diabetes Metab Res Rev. 2002;18(Suppl 3):S21–S26. [PubMed: 12324981]
6.
National Institute of Diabetes and Digestive and Kidney Diseases. National Diabetes Statistics, 2007 fact sheet. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health; 2008.
7.
Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28(2):103–117. [PubMed: 7587918]
8.
Anonymous. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854–865. [PubMed: 9742977]
9.
Anonymous. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–853. [PubMed: 9742976]
10.
Anonymous. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329(14):977–986. [PubMed: 8366922]
11.
Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589. [PubMed: 18784090]
12.
Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–139. [PubMed: 19092145]
13.
Gerstein HC, Miller ME. Effects of intensive glucose lowering in type 2 diabetes. Action to Control Cardiovascular Risk in Diabetes Study Group. N Engl J Med. 2008;358(24):2545–2559. [PMC free article: PMC4551392] [PubMed: 18539917]
14.
Shichiri M, Kishikawa H, Ohkubo Y, et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000;23(Suppl 2):B21–B29. [PubMed: 10860187]
15.
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–2471. [PubMed: 17517853]
16.
Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009 [PubMed: 19501900]
17.
Alexander GC, Sehgal NL, Moloney RM, et al. National trends in treatment of type 2 diabetes mellitus, 1994–2007. Arch Intern Med. 2008;168(19):2088–2094. [PMC free article: PMC2868588] [PubMed: 18955637]
18.
Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA. 2010;304(4):411–418. [PubMed: 20584880]
19.
Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. 2010 [PubMed: 20656674]
20.
Mann DM, Woodward M, Ye F, et al. Trends in medication use among US adults with diabetes mellitus: glycemic control at the expense of controlling cardiovascular risk factors. Arch Intern Med. 2009;169(18):1718–1720. [PubMed: 19822830]
21.
Bolen S, Wilson L, Vassy J, et al. Comparative Effectiveness and Safety of Oral Diabetes Medications for Adults with Type 2 Diabetes, Comparative Effectiveness Review No 8 (Prepared by the Johns Hopkins Evidence-based Practice Center under Contract No 290-02-0018). Rockville, MD: Agency for Healthcare Research and Quality; 2007. [PubMed: 20704051]
22.
Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203. [PMC free article: PMC2606813] [PubMed: 18945920]
23.
Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540–559. [PubMed: 19858063]
24.
Institute of Medicine. Clinical Practice Guidelines: Directions for a New Program. Washington, DC: National Academy Press; 1990. [PubMed: 25144032]
25.
Berlin JA. Does blinding of readers affect the results of meta-analyses? University of Pennsylvania Meta-analysis Blinding Study Group. Lancet. 1997;350(9072):185–186. [PubMed: 9250191]
26.
Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12. [PubMed: 8721797]
27.
Guide for Conducting Comparative Effectiveness Reviews. Rockville, MD: Agency for Healthcare Research and Quality; 2007.
28.
Segal JB, Brotman DJ, Emadi A, et al. Outcomes of Genetic Testing in Adults with a History of Venous Thromboembolism, Evidence Report No 180 AHRQ Publication No 09-E011 edition. Rockville, MD: Agency for Healthcare Research and Quality; 2009. [PMC free article: PMC4781326] [PubMed: 20629476]
29.
Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews for Interventions Version 5.0.2 [updated September 2009] The Cochrane Collaboration [Web page]
30.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188. [PubMed: 3802833]
31.
Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27(5):335–371. [PubMed: 2858114]
32.
Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004;23(9):1351–1375. [PubMed: 15116347]
33.
Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60. [PMC free article: PMC192859] [PubMed: 12958120]
34.
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–1101. [PubMed: 7786990]
35.
Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634. [PMC free article: PMC2127453] [PubMed: 9310563]
36.
Tosi F, Muggeo M, Brun E, et al. Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study. Metabolism. 2003;52(7):862–867. [PubMed: 12870162]
37.
Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281(21):2005–2012. [PubMed: 10359389]
38.
Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427–2443. [PubMed: 17145742]
39.
Erdem G, Dogru T, Tasci I, et al. The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus. Diabetes Res Clin Pract. 2008;82(2):214–218. [PubMed: 18778865]
40.
Derosa G, Fogari E, Cicero AF, et al. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Hypertens Res. 2007;30(5):387–394. [PubMed: 17587750]
41.
Teramoto T, Yamada N, Shirai K, et al. Effects of pioglitazone hydrochloride on Japanese patients with type 2 diabetes mellitus. J Atheroscler Thromb. 2007;14(2):86–93. [PubMed: 17485893]
42.
Kim HJ, Kang ES, Kim DJ, et al. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. Clin Endocrinol (Oxf). 2007;66(2):282–289. [PubMed: 17224000]
43.
Nagasaka S, Aiso Y, Yoshizawa K, et al. Comparison of pioglitazone and metformin efficacy using homeostasis model assessment. Diabet Med. 2004;21(2):136–141. [PubMed: 14984448]
44.
Derosa G, Maffioli P, Salvadeo SA, et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technol Ther. 2010;12(3):233–240. [PubMed: 20151774]
45.
Kiyici S, Ersoy C, Kaderli A, et al. ffect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients. Diabetes Res Clin Pract. 2009;86(1):44–50. [PubMed: 19674806]
46.
Derosa G, Maffioli P, Salvadeo SA, et al. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60’s study. Metabolism. 2009 [PubMed: 19394976]
47.
Gupta AK, Smith SR, Greenway FL, Bray GA. Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome. Diabetes Obes Metab. 2009;11(4):330–337. [PMC free article: PMC2748337] [PubMed: 19267711]
48.
Iliadis F, Kadoglou NP, Hatzitolios A, et al. Metabolic effects of rosiglitazone and metformin in Greek patients with recently diagnosed type 2 diabetes. In Vivo. 2007;21(6):1107–1114. [PubMed: 18210765]
49.
Rosenstock J, Rood J, Cobitz A, et al. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab. 2006;8(6):650–660. [PubMed: 17026489]
50.
Yamanouchi T, Sakai T, Igarashi K, et al. Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes. Diabet Med. 2005;22(8):980–985. [PubMed: 16026361]
51.
Ramachandran A, Snehalatha C, Salini J, et al. Use of glimepiride and insulin sensitizers in the treatment of type 2 diabetes--a study in Indians. J Assoc Physicians India. 2004;52:459–463. [PubMed: 15645955]
52.
Schernthaner G, Matthews DR, Charbonnel B, et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab. 2004;89(12):6068–6076. [PubMed: 15579760]
53.
Lawrence JM, Reid J, Taylor GJ, et al. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. Diabetes Care. 2004;27(1):41–46. [PubMed: 14693964]
54.
Pavo I, Jermendy G, Varkonyi TT, et al. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab. 2003;88(4):1637–1645. [PubMed: 12679450]
55.
Hallsten K, Virtanen KA, Lonnqvist F, et al. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes. 2002;51(12):3479–3485. [PubMed: 12453903]
56.
Perez A, Zhao Z, Jacks R, et al. Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM. Curr Med Res Opin. 2009;25(12):2915–2923. [PubMed: 19827910]
57.
Kato T, Sawai Y, Kanayama H, et al. Comparative study of low-dose pioglitazone or metformin treatment in Japanese diabetic patients with metabolic syndrome. Exp Clin Endocrinol Diabetes. 2009;117(10):593–599. [PubMed: 19924605]
58.
Turkmen Kemal Y, Guvener Demirag N, Yildirir A, et al. Effects of rosiglitazone on plasma brain natriuretic peptide levels and myocardial performance index in patients with type 2 diabetes mellitus. Acta Diabetol. 2007;44(3):149–156. [PubMed: 17721754]
59.
Chien HH, Chang CT, Chu NF, et al. Effect of glyburide-metformin combination tablet in patients with type 2 diabetes. J Chin Med Assoc. 2007;70(11):473–480. [PubMed: 18063500]
60.
Derosa G, Franzetti I, Gadaleta G, et al. Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin. Diabetes Nutr Metab. 2004;17(3):143–150. [PubMed: 15334791]
61.
Garber AJ, Donovan DS Jr, Dandona P, et al. Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J Clin Endocrinol Metab. 2003;88(8):3598–3604. [PubMed: 12915642]
62.
Goldstein BJ, Pans M, Rubin CJ. Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea. Clin Ther. 2003;25(3):890–903. [PubMed: 12852706]
63.
Blonde L, Rosenstock J, Mooradian AD, et al. Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy. Diabetes Obes Metab. 2002;4(6):368–375. [PubMed: 12406033]
64.
Marre M, Howlett H, Lehert P, et al. Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in Type 2 diabetic patients inadequately controlled on metformin. Diabet Med. 2002;19(8):673–680. [PubMed: 12147149]
65.
Garber AJ, Larsen J, Schneider SH, et al. Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes Obes Metab. 2002;4(3):201–208. [PubMed: 12047399]
66.
Amador-Licona N, Guizar-Mendoza J, Vargas E, et al. The short-term effect of a switch from glibenclamide to metformin on blood pressure and microalbuminuria in patients with type 2 diabetes mellitus. Arch Med Res. 2000;31(6):571–575. [PubMed: 11257323]
67.
Campbell IW, Menzies DG, Chalmers J, et al. One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabete Metab. 1994;20(4):394–400. [PubMed: 7843470]
68.
Hermann LS, Schersten B, Bitzen PO, et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care. 1994;17(10):1100–1109. [PubMed: 7821128]
69.
Hermann LS, Bitzen PO, Kjellstrom T, et al. Comparative efficacy of metformin and glibenclamide in patients with non-insulin-dependent diabetes mellitus. Diabete Metab. 1991;17(1 Pt 2):201–208. [PubMed: 1936477]
70.
DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995;333(9):541–549. [PubMed: 7623902]
71.
Charpentier G, Fleury F, Kabir M, et al. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet Med. 2001;18(10):828–834. [PubMed: 11678974]
72.
Turner R, Murchison L, Wright AD, et al. United Kingdom prospective diabetes study 24: A 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med. 1998;128(3):165–175. [PubMed: 9454524]
73.
U. K. prospective diabetes study. II. Reduction in HbA1c with basal insulin supplement, sulfonylurea, or biguanide therapy in maturity-onset diabetes. A multicenter study. Diabetes. 1985;34(8):793–798. [PubMed: 2862087]
74.
United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ. 1995;310(6972):83–88. [PMC free article: PMC2548496] [PubMed: 7833731]
75.
Goldstein BJ, Feinglos MN, Lunceford JK, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007;30(8):1979–1987. [PubMed: 17485570]
76.
Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Curr Med Res Opin. 2009;25(3):569–583. [PubMed: 19232032]
77.
Aschner P, Katzeff HL, Guo H, et al. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12(3):252–261. [PubMed: 20070351]
78.
Jadzinsky M, Pfutzner A, Paz-Pacheco E, et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab. 2009;11(6):611–622. [PubMed: 19515181]
79.
Horton ES, Clinkingbeard C, Gatlin M, et al. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care. 2000;23(11):1660–1665. [PubMed: 11092289]
80.
Horton ES, Foley JE, Shen SG, et al. Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naive patients with type 2 diabetes. Curr Med Res Opin. 2004;20(6):883–889. [PubMed: 15200747]
81.
Derosa G, Mugellini A, Ciccarelli L, et al. Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Res Clin Pract. 2003;60(3):161–169. [PubMed: 12757988]
82.
Moses R, Slobodniuk R, Boyages S, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 1999;22(1):119–124. [PubMed: 10333912]
83.
Leiter LA, Harris SB, Chiasson J-L, et al. Efficacy and safety of Rosiglitazone as monotherapy or in combination with metformin in primary care settings. Can J Diabetes. 2005;29(4):384–392.
84.
Kaku K. Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trial. Curr Med Res Opin. 2009;25(5):1111–1119. [PubMed: 19309251]
85.
Scott R, Loeys T, Davies MJ, et al. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2008;10(10):959–969. [PubMed: 18201203]
86.
Weissman P, Goldstein BJ, Rosenstock J, et al. Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study. Curr Med Res Opin. 2005;21(12):2029–2035. [PubMed: 16368054]
87.
Bailey CJ, Bagdonas A, Rubes J, et al. Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study. Clin Ther. 2005;27(10):1548–1561. [PubMed: 16330291]
88.
Gomez-Perez FJ, Fanghanel-Salmon G, Antonio Barbosa J, et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev. 2002;18(2):127–134. [PubMed: 11994904]
89.
Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther. 2000;22(12):1395–1409. [PubMed: 11192132]
90.
Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA. 2000;283(13):1695–1702. [PubMed: 10755495]
91.
Feinglos M, Dailey G, Cefalu W, et al. Effect on glycemic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM. Diabetes Res Clin Pract. 2005;68(2):167–175. [PubMed: 15860246]
92.
Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32(1):84–90. [PMC free article: PMC2606836] [PubMed: 18931095]
93.
Raz I, Chen Y, Wu M, et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin. 2008;24(2):537–550. [PubMed: 18194595]
94.
Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29(12):2638–2643. [PubMed: 17130197]
95.
DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009;32(9):1649–1655. [PMC free article: PMC2732156] [PubMed: 19478198]
96.
Marre M, Van Gaal L, Usadel KH, et al. Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients. Diabetes Obes Metab. 2002;4(3):177–186. [PubMed: 12047396]
97.
Khan MA, St Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care. 2002;25(4):708–711. [PubMed: 11919129]
98.
Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005;28(7):1547–1554. [PubMed: 15983299]
99.
Vijay SK, Mishra M, Kumar H, et al. Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes. Acta Diabetol. 2009;46(1):27–33. [PubMed: 18758684]
100.
Hanefeld M, Patwardhan R, Jones NP. A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes. Nutr Metab Cardiovasc Dis. 2007;17(1):13–23. [PubMed: 17174222]
101.
Jain R, Osei K, Kupfer S, et al. Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus. Pharmacotherapy. 2006;26(10):1388–1395. [PubMed: 16999648]
102.
Nakamura T, Matsuda T, Kawagoe Y, et al. Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. Metabolism. 2004;53(10):1382–1386. [PubMed: 15375799]
103.
Nakamura T, Ushiyama C, Shimada N, et al. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. J Diabetes Complications. 2000;14(5):250–254. [PubMed: 11113686]
104.
Bakris G, Viberti G, Weston WM, et al. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens. 2003;17(1):7–12. [PubMed: 12571611]
105.
Pfutzner A, Marx N, Lubben G, et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol. 2005;45(12):1925–1931. [PubMed: 15963388]
106.
Tan MH, Johns D, Strand J, et al. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes. Diabet Med. 2004;21(8):859–866. [PubMed: 15270789]
107.
Tan M, Johns D, Gonzalez Galvez G, et al. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial. Clin Ther. 2004;26(5):680–693. [PubMed: 15220012]
108.
Nakamura T, Sugaya T, Kawagoe Y, et al. Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria. Diabetes Metab Res Rev. 2006;22(5):385–389. [PubMed: 16506273]
109.
Raskin P, McGill J, Saad MF, et al. Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone. Diabet Med. 2004;21(4):329–335. [PubMed: 15049934]
110.
Jovanovic L, Hassman DR, Gooch B, et al. Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone. Diabetes Res Clin Pract. 2004;63(2):127–134. [PubMed: 14739053]
111.
Scott R, Wu M, Sanchez M, et al. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract. 2007;61(1):171–180. [PubMed: 17156104]
112.
Jibran R, Suliman MI, Qureshi F, et al. Safety and efficay of repaglinide compared with glibenclamide in the management of type 2 diabetic Pakistani patients. Pak. J. Med. Sci. 2006;22(4):385–390.
113.
Derosa G, Mugellini A, Ciccarelli L, et al. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. Clin Ther. 2003;25(2):472–484. [PubMed: 12749508]
114.
Madsbad S, Kilhovd B, Lager I, et al. Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study. Diabet Med. 2001;18(5):395–401. [PubMed: 11472451]
115.
Landgraf R, Bilo HJ, Muller PG. A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas. Eur J Clin Pharmacol. 1999;55(3):165–171. [PubMed: 10379630]
116.
Wolffenbuttel BH, Landgraf R. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group. Diabetes Care. 1999;22(3):463–467. [PubMed: 10097930]
117.
Marbury T, Huang WC, Strange P, et al. Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res Clin Pract. 1999;43(3):155–166. [PubMed: 10369424]
118.
Wolffenbuttel BH, Nijst L, Sels JP, et al. Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM. Eur J Clin Pharmacol. 1993;45(2):113–116. [PubMed: 8223830]
119.
Vakkilainen J, Mero N, Schweizer A, et al. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes. Diabetes Metab Res Rev. 2002;18(6):484–490. [PubMed: 12469362]
120.
Madsbad S, Schmitz O, Ranstam J, et al. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care. 2004;27(6):1335–1342. [PubMed: 15161785]
121.
Seino Y, Rasmussen MF, Nishida T, et al. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. Curr Med Res Opin. 2010 [PubMed: 20199137]
122.
Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373(9662):473–481. [PubMed: 18819705]
123.
Hamann A, Garcia-Puig J, Paul G, et al. Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone. Exp Clin Endocrinol Diabetes. 2008;116(1):6–13. [PubMed: 18095238]
124.
Home PD, Jones NP, Pocock SJ, et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabet Med. 2007;24(6):626–634. [PMC free article: PMC1974811] [PubMed: 17517066]
125.
Bakris GL, Ruilope LM, McMorn SO, et al. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens. 2006;24(10):2047–2055. [PubMed: 16957566]
126.
Umpierrez G, Issa M, Vlajnic A. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. Curr Med Res Opin. 2006;22(4):751–759. [PubMed: 16684436]
127.
Derosa G, Gaddi AV, Piccinni MN, et al. Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. Pharmacotherapy. 2005;25(5):637–645. [PubMed: 15899724]
128.
Garber A, Klein E, Bruce S, et al. Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2006;8(2):156–163. [PubMed: 16448519]
129.
Comaschi M, Demicheli A, Di Pietro C, et al. Effects of pioglitazone in combination with metformin or a sulfonylurea compared to a fixed-dose combination of metformin and glibenclamide in patients with type 2 diabetes. Diabetes Technol Ther. 2007;9(4):387–398. [PubMed: 17705695]
130.
Rigby SP, Handelsman Y, Lai YL, et al. Effects of Colesevelam HCl, Rosiglitazone, or Sitagliptin on Glycemic Control and the Lipid Profile in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy. Endocr Pract. 2009:1–34. [PubMed: 19789153]
131.
Raskin P, Lewin A, Reinhardt R, et al. Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/metformin tablet. Diabetes Obes Metab. 2009 [PubMed: 19476470]
132.
Defronzo RA, Triplitt C, Qu Y, et al. Effects Of Exenatide Plus Rosiglitazone On Beta Cell Function And Insulin Sensitivity In Subjects With Type 2 Diabetes On Metformin. Diabetes Care. 2010 [PMC free article: PMC2858197] [PubMed: 20107105]
133.
Nauck MA, Meininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007;9(2):194–205. [PubMed: 17300595]
134.
Seck T, Nauck M, Sheng D, et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: A 2-year study. International Journal of Clinical Practice: Int. J. Clin. Pract. 2010;64(5):562–576. [PubMed: 20456211]
135.
Derosa G, D’Angelo A, Fogari E, et al. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. J Clin Pharm Ther. 2009;34(1):13–23. [PubMed: 19125899]
136.
Gerich J, Raskin P, Jean-Louis L, et al. PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care. 2005;28(9):2093–2099. [PubMed: 16123472]
137.
Malone JK, Beattie SD, Campaigne BN, et al. Therapy after single oral agent failure: adding a second oral agent or an insulin mixture? Diabetes Res Clin Pract. 2003;62(3):187–195. [PubMed: 14625133]
138.
Kvapil M, Swatko A, Hilberg C, et al. Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes. Diabetes Obes Metab. 2006;8(1):39–48. [PubMed: 16367881]
139.
Yang J, Di F, He R, et al. Efffect of addition of low-dose rosiglitazone to sulphonylurea therapy on glycemic control in type 2 diabetic patients. Chin Med J (Engl). 2003;116(5):785–787. [PubMed: 12875702]
140.
Hanefeld M, Brunetti P, Schernthaner GH, et al. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care. 2004;27(1):141–147. [PubMed: 14693980]
141.
van der Meer RW, Rijzewijk LJ, de Jong HW, et al. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. Circulation. 2009;119(15):2069–2077. [PubMed: 19349323]
142.
Seufert J, Urquhart R. 2-year effects of pioglitazone add-on to sulfonylurea or metformin on oral glucose tolerance in patients with type 2 diabetes. Diabetes Res Clin Pract. 2008;79(3):453–460. [PubMed: 18160120]
143.
Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375(9724):1447–1456. [PubMed: 20417856]
144.
Bunck MC, Diamant M, Corner A, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care. 2009;32(5):762–768. [PMC free article: PMC2671094] [PubMed: 19196887]
145.
Robbins DC, Beisswenger PJ, Ceriello A, et al. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison. Clin Ther. 2007;29(11):2349–2364. [PubMed: 18158076]
146.
Raskin PR, Hollander PA, Lewin A, et al. Basal insulin or premix analogue therapy in type 2 diabetes patients. Eur J Intern Med. 2007;18(1):56–62. [PubMed: 17223044]
147.
Davies MJ, Thaware PK, Tringham JR, et al. A randomized controlled trial examining combinations of repaglinide, metformin and NPH insulin. Diabet Med. 2007;24(7):714–719. [PubMed: 17403126]
148.
Natali A, Baldeweg S, Toschi E, et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care. 2004;27(6):1349–1357. [PubMed: 15161787]
149.
St John Sutton M, Rendell M, Dandona P, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care. 2002;25(11):2058–2064. [PubMed: 12401757]
150.
Tolman KG, Freston JW, Kupfer S, et al. Liver safety in patients with type 2 diabetes treated with pioglitazone: Results from a 3-year, randomized, comparator-controlled study in the US. Drug Saf. 2009;32(9):787–800. [PubMed: 19670918]
151.
Derosa G, Cicero AF, Gaddi AV, et al. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial. Clin Ther. 2005;27(9):1383–1391. [PubMed: 16291411]
152.
Schwarz SL, Gerich JE, Marcellari A, et al. Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naive elderly patients with type 2 diabetes. Diabetes Obes Metab. 2008;10(8):652–660. [PubMed: 17941876]
153.
Hallsten K, Virtanen KA, Lonnqvist F, et al. Enhancement of insulin-stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone. Diabet Med. 2004;21(12):1280–1287. [PubMed: 15569129]
154.
Virtanen KA, Hallsten K, Parkkola R, et al. Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects. Diabetes. 2003;52(2):283–290. [PubMed: 12540598]
155.
Hermann LS, Kjellstrom T, Nilsson-Ehle P. Effects of metformin and glibenclamide alone and in combination on serum lipids and lipoproteins in patients with non-insulin-dependent diabetes mellitus. Diabete Metab. 1991;17(1 Pt 2):174–179. [PubMed: 1936472]
156.
Stewart MW, Cirkel DT, Furuseth K, et al. Effect of metformin plus roziglitazone compared with metformin alone on glycaemic control in well-controlled Type 2 diabetes. Diabet Med. 2006;23(10):1069–1078. [PubMed: 16978370]
157.
Derosa G, Gaddi AV, Piccinni MN, et al. Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial. Diabetes Obes Metab. 2006;8(2):197–205. [PubMed: 16448524]
158.
Comaschi M, Corsi A, Di Pietro C, et al. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia. Nutr Metab Cardiovasc Dis. 2008;18(5):373–379. [PubMed: 17919894]
159.
Derosa G, Gaddi AV, Ciccarelli L, et al. Long-term effect of glimepiride and rosiglitazone on non-conventional cardiovascular risk factors in metformin-treated patients affected by metabolic syndrome: a randomized, double-blind clinical trial. J Int Med Res. 2005;33(3):284–294. [PubMed: 15938589]
160.
Jonker JT, Lamb HJ, van der Meer RW, et al. Pioglitazone Compared with Metformin Increases Pericardial Fat Volume in Patients with Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. 2009 [PubMed: 19915017]
161.
Saydah SH, Eberhardt MS, Loria CM, et al. Age and the burden of death attributable to diabetes in the United States. Am J Epidemiol. 2002;156(8):714–719. [PubMed: 12370159]
162.
Kirk JK, D’Agostino RB Jr, Bell RA, et al. Disparities in HbA1c levels between African-American and non-Hispanic white adults with diabetes: a meta-analysis. Diabetes Care. 2006;29(9):2130–2136. [PMC free article: PMC3557948] [PubMed: 16936167]
163.
Saydah S, Cowie C, Eberhardt MS, et al. Race and ethnic differences in glycemic control among adults with diagnosed diabetes in the United States. Ethn Dis. 2007;17(3):529–535. [PubMed: 17985509]
164.
Malone JK, Kerr LF, Campaigne BN, et al. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther. 2004;26(12):2034–2044. [PubMed: 15823767]
165.
Malone JK, Bai S, Campaigne BN, et al. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes. Diabet Med. 2005;22(4):374–381. [PubMed: 15787659]
166.
Simpson SH, Majumdar SR, Tsuyuki RT, et al. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ. 2006;174(2):169–174. [PMC free article: PMC1329454] [PubMed: 16415461]
167.
Johnson JA, Simpson SH, Toth EL, et al. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes. Diabet Med. 2005;22(4):497–502. [PubMed: 15787679]
168.
Johnson JA, Majumdar SR, Simpson SH, et al. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care. 2002;25(12):2244–2248. [PubMed: 12453968]
169.
Eurich DT, Majumdar SR, McAlister FA, et al. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005;28(10):2345–2351. [PubMed: 16186261]
170.
Gulliford M, Latinovic R. Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study. Diabetes Metab Res Rev. 2004;20(3):239–245. [PubMed: 15133756]
171.
Tzoulaki I, Molokhia M, Curcin V, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ. 2009;339:1–9. [PMC free article: PMC2788912] [PubMed: 19959591]
172.
Azoulay L, Schneider-Lindner V, Dell’aniello S, et al. Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study. Pharmacoepidemiol Drug Saf. 2010;19(4):335–342. [PubMed: 20052677]
173.
Hsiao FY, Huang WF, Wen YW, et al. Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan. Drug Saf. 2009;32(8):675–690. [PubMed: 19591532]
174.
Pantalone KM, Kattan MW, Yu C, et al. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol. 2009;46(2):145–154. [PubMed: 19194648]
175.
Kahler KH, Rajan M, Rhoads GG, et al. Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration. Diabetes Care. 2007;30(7):1689–1693. [PubMed: 17440170]
176.
Evans JM, Ogston SA, Emslie-Smith A, et al. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia. 2006;49(5):930–936. [PubMed: 16525843]
177.
Fisman EZ, Tenenbaum A, Boyko V, et al. Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up. Clin Cardiol. 2001;24(2):151–158. [PMC free article: PMC6655246] [PubMed: 11460818]
178.
Fisman EZ, Tenenbaum A, Benderly M, et al. Antihyperglycemic treatment in diabetics with coronary disease: increased metformin-associated mortality over a 5-year follow-up. Cardiology. 1999;91(3):195–202. [PubMed: 10516414]
179.
Jones TA, Sautter M, Van Gaal LF, et al. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. Diabetes Obes Metab. 2003;5(3):163–70. [PubMed: 12681023]
180.
Monami M, Marchionni N, Masotti G, et al. Effect of combined secretagogue/biguanide treatment on mortality in type 2 diabetic patients with and without ischemic heart disease. Int J Cardiol. 2008;126(2):247–251. [PubMed: 17512619]
181.
McAfee AT, Koro C, Landon J, et al. Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol Drug Saf. 2007;16(7):711–725. [PubMed: 17551989]
182.
Brownstein JS, Murphy SN, Goldfine AB, et al. Rapid identification of myocardial infarction risk associated with diabetes medications using electronic medical records. Diabetes Care. 2010;33(3):526–531. [PMC free article: PMC2827502] [PubMed: 20009093]
183.
Rosak C, Standl E, Reblin T, et al. Rosiglitazone is effective and well-tolerated in a range of therapeutic regimens during daily practice in patients with type 2 diabetes. Int J Clin Pract. 2006;60(9):1040–1047. [PubMed: 16939544]
184.
Agarwal R, Saha C, Battiwala M, et al. A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy. Kidney Int. 2005;68(1):285–292. [PubMed: 15954919]
185.
Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12(5):442–451. [PubMed: 20415693]
186.
Hu YY, Ye SD, Zhao LL, et al. Hydrochloride pioglitazone decreases urinary cytokines excretion in type 2 diabetes. Clin Endocrinol (Oxf). 2010;73(6):739–743. [PubMed: 20874769]
187.
Sillars B, Davis WA, Hirsch IB, et al. Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study. Diabetes Obes Metab. 2010;12(9):757–765. [PubMed: 20649627]
188.
Loebstein R, Dushinat M, Vesterman-Landes J, et al. Database Evaluation of the Effects of Long-Term Rosiglitazone Treatment on Cardiovascular Outcomes in Patients With Type 2 Diabetes. J Clin Pharmacol. 2010 [PubMed: 20484611]
189.
U.S. Food and Drug Adminstration. Center for Drug Evaluation and Research. Medical Review for Avandia. Application number 021071. 1999.
190.
U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Medical Review for Glucovance, Application number 21–178. 2000.
191.
U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Medical Review for Janumet, Application number 22–044. 2007.
192.
U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Supplemental Medical Officer Review for Metformin/Glyburide, Application number 21–178. 2002.
193.
U.S. Food and Drug Adminsitration. Center for Drug Evaluation and Research. Medical Review for Metformin/Glipizide, Application Number 21–460. 2002.
194.
Rajagopalan R, Iyer S, Khan M. Effect of pioglitazone on metabolic syndrome risk factors: results of double-blind, multicenter, randomized clinical trials. Curr Med Res Opin. 2005;21(1):163–172. [PubMed: 15881488]
195.
Maru S, Koch GG, Stender M, et al. Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting. Diabetes Care. 2005;28(1):20–26. [PubMed: 15616228]
196.
Nichols GA, Koro CE, Gullion CM, et al. The incidence of congestive heart failure associated with antidiabetic therapies. Diabetes Metab Res Rev. 2005;21(1):51–57. [PubMed: 15386819]
197.
Lund SS, Tarnow L, Stehouwer CD, et al. Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial. Diabetes Obes Metab. 2007;9(3):394–407. [PubMed: 17391168]
198.
Wright AD, Cull CA, Macleod KM, et al. Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73. J Diabetes Complications. 2006;20(6):395–401. [PubMed: 17070446]
199.
Dimic D, Velojic Golubovic M, Antic S, et al. Evaluation of the repaglinide efficiency in comparison to the glimepiride in the type 2 diabetes patients poorly regulated by the metmorfine administration. Bratislava Med J. 2009;110(6):335–339. [PubMed: 19634573]
200.
Asche CV, McAdam-Marx C, Shane-McWhorter L, et al. Evaluation of adverse events of oral antihyperglycemic monotherapy experienced by a geriatric population in a real-world setting: a retrospective cohort analysis. Drugs Aging. 2008;25(7):611–622. [PubMed: 18582148]
201.
Hanefeld M, Pfutzner A, Forst T, et al. Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study. Curr Med Res Opin. 2006;22(6):1211–1215. [PubMed: 16846554]
202.
Hussein Z, Wentworth JM, Nankervis AJ, et al. Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real-life experience from a tertiary hospital. Med J Aust. 2004;181(10):536–539. [PubMed: 15540964]
203.
Mafauzy M. Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting. Diabetes Res Clin Pract. 2002;58(1):45–53. [PubMed: 12161056]
204.
Blevins T. Therapeutic options that provide glycemic control and weight loss for patients with type 2 diabetes. Postgrad Med. 2010;122(1):172–183. [PubMed: 20107301]
205.
Mourad C, Chevalier S, Morais JA, et al. Antihyperglycaemic medication modifies factors of postprandial satiety in type 2 diabetes. Diabestes Obes. Metab. 2009;11(8):819–822. [PubMed: 19476475]
206.
Rajagopalan R, Iyer S, Perez A. Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone. Diabetes Obes Metab. 2005;7(2):161–169. [PubMed: 15715889]
207.
Karter AJ, Ahmed AT, Liu J, et al. Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet Med. 2005;22(8):986–993. [PMC free article: PMC3557913] [PubMed: 16026362]
208.
McAlister FA, Eurich DT, Majumdar SR, et al. The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. Eur J Heart Fail. 2008;10(7):703–708. [PubMed: 18571471]
209.
Hartung DM, Touchette DR, Bultemeier NC, et al. Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study. Pharmacotherapy. 2005;25(10):1329–1336. [PubMed: 16185176]
210.
Juurlink DN, Gomes T, Lipscombe LL, et al. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ. 2009;339:b2942. [PMC free article: PMC2728804] [PubMed: 19690342]
211.
Singh S, Mukherjee KK, Gill KD, et al. Lead-induced peripheral neuropathy following ayurvedic medication. Indian J Med Sci. 2009;63(9):408–410. [PubMed: 19805920]
212.
Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52(9):1766–1777. [PubMed: 19572116]
213.
Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2008;31(5):845–851. [PubMed: 18223031]
214.
Mancini T, Mazziotti G, Doga M, et al. Vertebral fractures in males with type 2 diabetes treated with rosiglitazone. Bone. 2009;45(4):784–788. [PubMed: 19527806]
215.
Dormuth CR, Carney G, Carleton B, et al. Thiazolidinediones and fractures in men and women. Arch Intern Med. 2009;169(15):1395–1402. [PubMed: 19667303]
216.
Mathieu C. The scientific evidence: vildagliptin and the benefits of islet enhancement. Diabetes Obes Metab. 2009;11( Suppl 2):9–17. [PubMed: 19385979]
217.
European Medicines Agency. Scientific Discussion for Actos. 2004.
218.
U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Medical Review for Rosiglitazone, Application Number 21-071/001. 2000.
219.
GlaxoSmithKline I. Product Monograph for Avandia. Submission Control. 2009;(119390)
220.
Chou HS, Palmer JP, Jones Ar, et al. Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes. Diabetes Obes Metab. 2008;10(8):626–637. [PubMed: 17645558]
221.
Kawai T, Funae O, Shimada A, et al. Effects of pretreatment with low-dose metformin on metabolic parameters and weight gain by pioglitazone in Japanese patients with type 2 diabetes. Intern Med. 2008;47(13):1181–1188. [PubMed: 18591838]
222.
United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group. Ann Intern Med. 1998;128(3):165–175. [PubMed: 9454524]
223.
Giles TD, Miller AB, Elkayam U, et al. Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction. J Card Fail. 2008;14(6):445–452. [PubMed: 18672190]
224.
Horsdal HT, Johnsen SP, Sondergaard F, et al. Type of preadmission glucose-lowering treatment and prognosis among patients hospitalised with myocardial infarction: a nationwide follow-up study. Diabetologia. 2008;51(4):567–574. [PubMed: 18283428]
225.
Hermann LS, Schersten B, Melander A. Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination. Diabet Med. 1994;11(10):953–960. [PubMed: 7895460]
226.
Belcher G, Lambert C, Goh KL, et al. Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide. Int J Clin Pract. 2004;58(9):833–837. [PubMed: 15529516]
227.
Khan M, Xu Y, Edwards G, et al. Effects of pioglitazone on the components of diabetic dyslipidaemia: results of double-blind, multicentre, randomised studies. Int J Clin Pract. 2004;58(10):907–912. [PubMed: 15587767]
228.
Lester JW, Fernandes AW. Pioglitazone in a subgroup of patients with type 2 diabetes meeting the criteria for metabolic syndrome. Int J Clin Pract. 2005;59(2):134–142. [PubMed: 15854187]
229.
Perez A, Khan M, Johnson T, et al. Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes. Diab Vasc Dis Res. 2004;1(1):44–50. [PubMed: 16305056]
230.
Belcher G, Schernthaner G. Changes in liver tests during 1-year treatment of patients with Type 2 diabetes with pioglitazone, metformin or gliclazide. Diabet Med. 2005;22(8):973–979. [PubMed: 16026360]
231.
Belcher G, Lambert C, Edwards G, et al. Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes. Diabetes Res Clin Pract. 2005;70(1):53–62. [PubMed: 16002175]
232.
Charbonnel B, Schernthaner G, Brunetti P, et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia. 2005;48(6):1093–1104. [PubMed: 15889234]
233.
Ceriello A, Johns D, Widel M, et al. Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes. Diabetes Care. 2005;28(2):266–272. [PubMed: 15677777]
234.
Rendell MS, Glazer NB, Ye Z. Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with Type 2 diabetes: influence of prior antidiabetic drug regimen. J Diabetes Complications. 2003;17(4):211–217. [PubMed: 12810245]
235.
Monami M, Lamanna C, Marchionni N, et al. Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract. 2008;79(2):196–203. [PubMed: 17931733]
236.
Phung OJ, Scholle JM, Talwar M, et al. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA. 2010;303(14):1410–1418. [PubMed: 20388897]
237.
Kahn BB, Flier JS. Obesity and insulin resistance. J. Clin. Invest. 2000;106(4):473–481. [PMC free article: PMC380258] [PubMed: 10953022]
238.
Monami M, Marchionni N, Mannucci E. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. Eur J Endocrinol. 2009;160(6):909–917. [PubMed: 19318378]
239.
Barrera JG, D’Alessio DA, Drucker DJ, et al. Differences in the central anorectic effects of glucagon-like peptide-1 and exendin-4 in rats. Diabetes. 2009;58(12):2820–2827. [PMC free article: PMC2780868] [PubMed: 19741167]
240.
Williams DL, Baskin DG, Schwartz MW. Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation. Diabetes. 2006;55(12):3387–3393. [PubMed: 17130484]
241.
Hu FB, Stampfer MJ, Solomon CG, et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med. 2001;161(14):1717–1723. [PubMed: 11485504]
242.
Selvin E, Bolen S, Yeh HC, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med. 2008;168(19):2070–2080. [PMC free article: PMC2765722] [PubMed: 18955635]
243.
Food and Drug Administration. Briefing document: July 13–14 2010 meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. [Accessed October 27, 2010]. [Web Page]
244.
Rosen CJ. Revisiting the rosiglitazone story—lessons learned. N Engl J Med. 2010;363(9):803–806. [PubMed: 20660395]
245.
Woodcock J, Sharfstein JM, Hamburg M. Regulatory action on rosiglitazone by the U.S. Food and Drug Administration. N Engl J Med. 2010;363(16):1489–1491. [PubMed: 20942663]
246.
Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Rosiglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007;(3):CD006063. [PMC free article: PMC7389529] [PubMed: 17636824]
247.
Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med. 2007;147(6):386–399. [PubMed: 17638715]
248.
Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007;370(9593):1129–1136. [PubMed: 17905165]
249.
Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007;298(10):1189–1195. [PubMed: 17848653]
250.
GlaxoSmithKline. AVANDIA package insert. [Accessed December 9, 2009]. Available at: http://us​.gsk.com/products​/assets/us_avandia.pdf.
251.
Takeda Pharmaceutical America. I. ACTOS package insert. [Accessed December 14, 2009]. Available at: http://general​.takedapharm​.com/content/file/pi​.pdf?applicationcode​=8a9c4571-a123-4477-91de-b9cafe7d07e3&filetypecode=actospi.
252.
Colucciello M. Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus. Arch Ophthalmol. 2005;123(9):1273–1275. [PubMed: 16157815]
253.
Ryan EH Jr, Han DP, Ramsay RC, et al. Diabetic macular edema associated with glitazone use. Retina. 2006;26(5):562–570. [PubMed: 16770264]
254.
Fong DS, Contreras R. Glitazone use associated with diabetic macular edema. Am J Ophthalmol. 2009;147(4):583–6. e1. [PubMed: 19181303]
255.
Noel RA, Braun DK, Patterson RE, et al. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care. 2009;32(5):834–838. [PMC free article: PMC2671118] [PubMed: 19208917]
256.
U.S. Food and Drug Administration. Exenatide (marketed as Byetta) Information. [Accessed December 14, 2009]. Available at: http://www​.fda.gov/Drugs​/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders​/ucm113705.htm.
257.
Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin. 2009;25(4):1019–1027. [PubMed: 19278373]
258.
Salpeter S, Greyber E, Pasternak G, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2006;(1):CD002967. [PubMed: 16437448]
259.
Bowker SL, Majumdar SR, Veugelers P, et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006;29(2):254–258. [PubMed: 16443869]
260.
Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 2009;52(9):1732–1744. [PMC free article: PMC2723679] [PubMed: 19565214]
261.
Bodmer M, Meier C, Krahenbuhl S, et al. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care. 2010 [PMC free article: PMC2875444] [PubMed: 20299480]
262.
Colhoun HM. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia. 2009;52(9):1755–1765. [PMC free article: PMC2723678] [PubMed: 19603149]
263.
Home PD, Kahn SE, Jones NP, et al. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia. 2010;53(9):1838–1845. [PMC free article: PMC2910882] [PubMed: 20532476]
264.
Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009;180(1):32–39. [PMC free article: PMC2612065] [PubMed: 19073651]
265.
Hsiao FY, Mullins CD. The association between thiazolidinediones and hospitalisation for fracture in type 2 diabetic patients: a Taiwanese population-based nested case-control study. Diabetologia. 2009 [PubMed: 19943156]
266.
Qayyum R, Wilson LM, Bolen S, et al. Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults with Type 2 Diabetes, Comparative Effectiveness Review No 14 edition. Rockville, MD: Agency for Healthcare Research and Quality; 2008. [PubMed: 20704037]
267.
Bazzano LA, Lee LJ, Shi L, et al. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: A meta-analysis of randomized controlled trials. Diabetic Med. 2008;25(8):924–932. [PubMed: 18959605]
268.
Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract. 2008;81(2):184–189. [PubMed: 18495286]
269.
Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2008;(2):CD006739. [PMC free article: PMC8985075] [PubMed: 18425967]
270.
Wani JH, John-Kalarickal J, Fonseca VA. Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review. Cardiol Clin. 2008;26(4):639–648. [PubMed: 18929237]
271.
U.S. Food and Drug Administration. Byetta (exenatide). [Accessed December 14, 2009]. Available at: http://www​.fda.gov/Safety​/MedWatch/SafetyInformation​/SafetyAlertsforHumanMedicalProducts/ucm079781​.htm.
272.
U.S. Food and Drug Administration. Byetta (exenatide)—Renal Failure. [Accessed December 14, 2009]. Available at: http://www​.fda.gov/Safety​/MedWatch/SafetyInformation​/SafetyAlertsforHumanMedicalProducts/ucm188703​.htm.
273.
Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann Intern Med. 2000;133(6):455–463. [PubMed: 10975964]
274.
Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279–1289. [PubMed: 16214598]
275.
Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–2559. [PMC free article: PMC4551392] [PubMed: 18539917]
276.
Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New Engl. J. Med. 2008;358(24):2560–2572. [PubMed: 18539916]
277.
Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008;299(13):1561–1573. [PubMed: 18378631]
278.
Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab. 2006;8(4):436–447. [PubMed: 16776751]
279.
Zinman B, Hoogwerf BJ, Duran Garcia S, et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2007;146(7):477–485. [PubMed: 17404349]
280.
Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27(11):2628–2635. [PubMed: 15504997]
281.
DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28(5):1092–1100. [PubMed: 15855572]
282.
Monami M, Lamanna C, Balzi D, et al. Sulphonylureas and cancer: a case-control study. Acta Diabetol. 2008 [PubMed: 19082520]
283.
Sadikot SM, Mogensen CE. Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study. Diabetes Res Clin Pract. 2008;82(3):391–395. [PubMed: 18945509]
284.
Bodmer M, Meier C, Krahenbuhl S, et al. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care. 2008;31(11):2086–2091. [PMC free article: PMC2571051] [PubMed: 18782901]
285.
Meier C, Kraenzlin ME, Bodmer M, et al. Use of thiazolidinediones and fracture risk. Arch Intern Med. 2008;168(8):820–825. [PubMed: 18443256]
286.
Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia. 2005;48(7):1292–1299. [PubMed: 15909154]
287.
Gallwitz B. The evolving place of incretin-based therapies in type 2 diabetes. Pediatr Nephrol. 2010 [PMC free article: PMC2874027] [PubMed: 20130920]
288.
Derosa G, D’Angelo A, Fogari E, et al. Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial. Intern Med. 2007;46(22):1837–1846. [PubMed: 18025765]
289.
Betteridge DJ, Verges B. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes. Diabetologia. 2005;48(12):2477–2481. [PubMed: 16283239]
290.
Langenfeld MR, Forst T, Hohberg C, et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation. 2005;111(19):2525–2531. [PubMed: 15883215]
291.
Smith SA, Porter LE, Biswas N, et al. Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin:insulin ratio in type 2 diabetes. J Clin Endocrinol Metab. 2004;89(12):6048–6053. [PubMed: 15579757]
292.
Komajda M, McMurray JJ, Beck-Nielsen H, et al. Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J. 2010;31(7):824–831. [PMC free article: PMC2848325] [PubMed: 20118174]

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (9.0M)